Mar 2, 2026 07:01AM
Mar 2, 2026 07:00AM
Feb 18, 2026 07:00AM
Feb 18, 2026 07:00AM
Feb 12, 2026 07:00AM
Jan 8, 2026 04:07PM
Jan 8, 2026 04:05PM KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
Dec 22, 2025 06:00AM
Dec 22, 2025 06:00AM
Nov 11, 2025 12:44AM
Nov 10, 2025 04:30PM
Nov 6, 2025 08:02AM
Nov 6, 2025 08:01AM
Nov 3, 2025 07:00AM KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025
Oct 30, 2025 07:00AM
Oct 6, 2025 04:00PM
Oct 6, 2025 04:00PM
Oct 6, 2025 07:00AM
Oct 6, 2025 07:00AM
Oct 2, 2025 07:00AM
Oct 2, 2025 07:00AM KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors
Sep 26, 2025 07:00AM
Sep 24, 2025 10:52PM
Sep 24, 2025 10:52PM
Sep 24, 2025 04:01PM
Sep 24, 2025 04:01PM
Sep 19, 2025 07:00AM
Sep 19, 2025 07:00AM KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema
Sep 12, 2025 04:06AM
Sep 11, 2025 07:04AM
Sep 11, 2025 07:02AM
Sep 11, 2025 07:00AM
Sep 4, 2025 07:05AM
Aug 11, 2025 07:00AM
Jul 25, 2025 08:00AM KalVista gets positive EU opinion for hereditary angioedema drug
Jul 25, 2025 08:00AM
Jul 15, 2025 04:05PM
Jul 15, 2025 04:05PM
Jul 10, 2025 10:29AM
Jul 10, 2025 07:00AM
Jul 7, 2025 06:31AM
Jul 7, 2025 06:30AM KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
Jun 26, 2025 07:02AM
Jun 26, 2025 07:00AM
Jun 16, 2025 07:03AM
Jun 16, 2025 07:00AM
Jun 13, 2025 04:06PM
Jun 13, 2025 04:05PM
Jun 5, 2025 07:00AM KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025
Jun 2, 2025 07:00AM

1,168,522 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All